Schlampp, Ingmar
Rieber, Juliane
Adeberg, Sebastian
Bozorgmehr, Farastuk
Heußel, Claus Peter
Steins, Martin
Kappes, Jutta
Hoffmann, Hans
Welzel, Thomas
Debus, Jürgen
Rieken, Stefan
Article History
Received: 3 June 2018
Accepted: 14 March 2019
First Online: 1 April 2019
Compliance with ethical guidelines
:
: C.P. Heußel is a stock owner of Stada and GSK and has received consultation and lecture fees and/or honoraria from Schering-Plough, Pfizer, Basilea, Boehringer Ingelheim, Novartis, Roche, Astellas, Gilead, MSD, Lilly, Intermune, Fresenius, Olympus, Essex, AstraZeneca, Bracco, MEDA Pharma, Chiesi, Siemens, Covidien, Pierre Fabre, Grifols and Bayer and research funding from Siemens, Pfizer, MeVis and Boehringer Ingelheim. I. Schlampp, J. Rieber, S. Adeberg, F. Bozorgmehr, M. Steins, J. Kappes, H. Hoffmann, T. Welzel, J. Debus and S. Rieken declare that they have no competing interests.
: All patients provided written informed consent after thorough information about treatment concepts and possible side effects. The responsible ethics committee approved the analysis.